Tag Archives: CD33 x CLL1 CAR-T

2Seventy Bio’s SC-DARIC-33 Program Paused

On Wednesday, June 14, 2seventy bio announced the pause of the Ph1 PLAT-08 trial, evaluating SC-DARIC33 (drug-regulated CD33 CAR-T) for pediatric and young adult r/r CD33+ AML by Seattle Children’s Hospital, sponsor of the study. The company informed the decision was taken in response to a recent Grade 5 SAE and was followed by the required notification to the FDA (press release). Below, Celltelligence provides insights on SC-DARIC-33’s biological profile and potential risks associated with the use of rapamycin while hypothesizing about the future of 2seventy programs in AML.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.